首页 > 最新文献

Current Opinion in Supportive and Palliative Care最新文献

英文 中文
Radiation therapy options in kidney cancer. 肾癌的放射治疗选择。
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-12-01 Epub Date: 2023-10-26 DOI: 10.1097/SPC.0000000000000683
Nicholas G Zaorsky, Alexander V Louie, Shankar Siva

Purpose of review: In this review, the authors discuss the use of stereotactic body radiation therapy (SBRT) for the treatment of primary and metastatic renal cell carcinoma (RCC).

Recent findings: For primary RCC treated with SBRT, local control is estimated at >95%, and grade 3-4 toxicity is limited at ≤5%. The difference in glomerular filtration rate pretreatment versus posttreatment was about 7.7 ml/min. For metastatic RCC treated with SBRT, the 1-year local control is ~90%. The incidence of any grade 3-4 toxicity is ~1%. Several ongoing trials are evaluating SBRT in combination or in lieu of systemic therapy. There are many unknowns remaining in the treatment of RCC, including tumor prognostication, treatment selection, and treatment delivery.

Summary: Stereotactic body radiation therapy is a safe and effective treatment option for patients with primary and metastatic RCC.

综述目的:在这篇综述中,作者讨论了立体定向身体放射治疗(SBRT)在原发性和转移性肾细胞癌(RCC)治疗中的应用。最近的研究结果:对于用SBRT治疗的原发性肾细胞瘤,局部控制估计>95%,3-4级毒性限制在≤5%。治疗前和治疗后肾小球滤过率的差异约为7.7ml/min。对于SBRT治疗的转移性RCC,1年的局部控制约为90%。任何3-4级毒性的发生率约为1%。几个正在进行的试验正在评估SBRT联合或代替全身治疗。RCC的治疗仍有许多未知因素,包括肿瘤预后、治疗选择和治疗交付。摘要:立体定向身体放射治疗是原发性和转移性RCC患者安全有效的治疗选择。
{"title":"Radiation therapy options in kidney cancer.","authors":"Nicholas G Zaorsky, Alexander V Louie, Shankar Siva","doi":"10.1097/SPC.0000000000000683","DOIUrl":"10.1097/SPC.0000000000000683","url":null,"abstract":"<p><strong>Purpose of review: </strong>In this review, the authors discuss the use of stereotactic body radiation therapy (SBRT) for the treatment of primary and metastatic renal cell carcinoma (RCC).</p><p><strong>Recent findings: </strong>For primary RCC treated with SBRT, local control is estimated at >95%, and grade 3-4 toxicity is limited at ≤5%. The difference in glomerular filtration rate pretreatment versus posttreatment was about 7.7 ml/min. For metastatic RCC treated with SBRT, the 1-year local control is ~90%. The incidence of any grade 3-4 toxicity is ~1%. Several ongoing trials are evaluating SBRT in combination or in lieu of systemic therapy. There are many unknowns remaining in the treatment of RCC, including tumor prognostication, treatment selection, and treatment delivery.</p><p><strong>Summary: </strong>Stereotactic body radiation therapy is a safe and effective treatment option for patients with primary and metastatic RCC.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":"17 4","pages":"308-314"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50159093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of corticosteroids in the palliation of dyspnea in cancer patients: an evidence-based review. 皮质类固醇在缓解癌症患者呼吸困难中的作用:循证综述。
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-12-01 Epub Date: 2023-09-29 DOI: 10.1097/SPC.0000000000000677
David Hui, Sriram Yennurajalingam

Purpose of review: To provide an evidence-based review on the use of corticosteroids for dyspnea in cancer patients.

Recent findings: Corticosteroids are commonly used for palliation of dyspnea; however, there is wide variation in how they are prescribed due to the paucity of high-quality evidence. Some clinicians would offer corticosteroids routinely regardless of the causes of dyspnea, while others would only prescribe corticosteroids selectively for specific indications, such as lymphangitic carcinomatosis, upper airway obstruction, superior vena cava obstruction, and cancer treatment-induced pneumonitis. Few mechanistic studies have been conducted to support the use of corticosteroids in cancer patients. Two double-blind, placebo-controlled randomized trials have examined the routine use of high-dose dexamethasone for dyspnea in cancer patients. A pilot study suggested some benefits, but the larger confirmatory trial revealed no improvement compared to the placebo and significantly more adverse events. The selective use of corticosteroids use is only based on observational studies such as case series.

Summary: The unfavorable risk:benefit ratio of high-dose dexamethasone suggests that it should not be routinely prescribed for dyspnea in cancer patients. More research is needed to assess the selective use of corticosteroids and identify patients most likely be benefit from corticosteroid use.

综述目的:对癌症患者使用皮质类固醇治疗呼吸困难进行循证综述。最近的发现:皮质类固醇通常用于缓解呼吸困难;然而,由于缺乏高质量的证据,它们的处方方式存在很大差异。一些临床医生会常规提供皮质类固醇,而不考虑呼吸困难的原因,而另一些临床医生只会选择性地为特定的适应症开皮质类固醇,如淋巴管癌、上气道阻塞、上腔静脉阻塞和癌症治疗诱导的肺炎。很少有机制研究支持在癌症患者中使用皮质类固醇。两项双盲、安慰剂对照的随机试验对癌症患者常规使用大剂量地塞米松治疗呼吸困难进行了研究。一项试点研究表明了一些益处,但更大规模的验证性试验显示,与安慰剂相比没有改善,不良事件明显更多。皮质类固醇的选择性使用仅基于观察性研究,如病例系列。摘要:大剂量地塞米松的不良风险收益比表明,癌症患者不应常规使用地塞米松治疗呼吸困难。需要更多的研究来评估皮质类固醇的选择性使用,并确定最有可能从皮质类固醇使用中受益的患者。
{"title":"The role of corticosteroids in the palliation of dyspnea in cancer patients: an evidence-based review.","authors":"David Hui, Sriram Yennurajalingam","doi":"10.1097/SPC.0000000000000677","DOIUrl":"10.1097/SPC.0000000000000677","url":null,"abstract":"<p><strong>Purpose of review: </strong>To provide an evidence-based review on the use of corticosteroids for dyspnea in cancer patients.</p><p><strong>Recent findings: </strong>Corticosteroids are commonly used for palliation of dyspnea; however, there is wide variation in how they are prescribed due to the paucity of high-quality evidence. Some clinicians would offer corticosteroids routinely regardless of the causes of dyspnea, while others would only prescribe corticosteroids selectively for specific indications, such as lymphangitic carcinomatosis, upper airway obstruction, superior vena cava obstruction, and cancer treatment-induced pneumonitis. Few mechanistic studies have been conducted to support the use of corticosteroids in cancer patients. Two double-blind, placebo-controlled randomized trials have examined the routine use of high-dose dexamethasone for dyspnea in cancer patients. A pilot study suggested some benefits, but the larger confirmatory trial revealed no improvement compared to the placebo and significantly more adverse events. The selective use of corticosteroids use is only based on observational studies such as case series.</p><p><strong>Summary: </strong>The unfavorable risk:benefit ratio of high-dose dexamethasone suggests that it should not be routinely prescribed for dyspnea in cancer patients. More research is needed to assess the selective use of corticosteroids and identify patients most likely be benefit from corticosteroid use.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":" ","pages":"270-276"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41161096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perioperative systemic therapy in renal cell carcinoma. 肾细胞癌的围手术期全身治疗。
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-12-01 Epub Date: 2023-10-06 DOI: 10.1097/SPC.0000000000000675
Ceilidh MacPhail, Lori A Wood, Myuran Thana

Purpose of review: Renal cell carcinoma (RCC) is the most common kidney neoplasm. Localized RCC can be cured with nephrectomy. However, a proportion of patients will recur with incurable distant metastatic disease. There is a clear need for treatments to reduce the risk of RCC recurrence and thus improve survival. This review describes the landscape of perioperative therapy for RCC, focusing on more recent trials involving immune checkpoint inhibitors (ICIs).

Recent findings: ICIs have significantly changed outcomes in advanced RCC. Four trials investigating the role of perioperative ICI for RCC are now reported. Only one trial utilizing adjuvant pembrolizumab (Keynote-564) has shown a disease-free survival benefit in resected RCC.

Summary: Patients with resected RCC should be counselled on their risk of recurrence and the potential option of adjuvant pembrolizumab, recognizing that overall survival data are not yet available.

综述目的:肾细胞癌(RCC)是最常见的肾脏肿瘤。局限性肾细胞癌可以通过肾切除术治愈。然而,有一部分患者会因无法治愈的远处转移性疾病而复发。显然需要治疗来降低RCC复发的风险,从而提高生存率。这篇综述描述了RCC围手术期治疗的前景,重点是最近涉及免疫检查点抑制剂(ICIs)的试验。最近的发现:ICIs显著改变了晚期RCC的结果。目前报道了四项研究围手术期ICI在RCC中作用的试验。只有一项使用辅助pembrolizumab的试验(Keynote-564)显示,切除的RCC具有无病生存益处。总结:应就其复发风险和辅助pembrulizumab治疗的潜在选择向切除的RCC患者提供咨询,同时认识到总体生存数据尚不可用。
{"title":"Perioperative systemic therapy in renal cell carcinoma.","authors":"Ceilidh MacPhail, Lori A Wood, Myuran Thana","doi":"10.1097/SPC.0000000000000675","DOIUrl":"10.1097/SPC.0000000000000675","url":null,"abstract":"<p><strong>Purpose of review: </strong>Renal cell carcinoma (RCC) is the most common kidney neoplasm. Localized RCC can be cured with nephrectomy. However, a proportion of patients will recur with incurable distant metastatic disease. There is a clear need for treatments to reduce the risk of RCC recurrence and thus improve survival. This review describes the landscape of perioperative therapy for RCC, focusing on more recent trials involving immune checkpoint inhibitors (ICIs).</p><p><strong>Recent findings: </strong>ICIs have significantly changed outcomes in advanced RCC. Four trials investigating the role of perioperative ICI for RCC are now reported. Only one trial utilizing adjuvant pembrolizumab (Keynote-564) has shown a disease-free survival benefit in resected RCC.</p><p><strong>Summary: </strong>Patients with resected RCC should be counselled on their risk of recurrence and the potential option of adjuvant pembrolizumab, recognizing that overall survival data are not yet available.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":" ","pages":"301-307"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41172155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of primary cancer in metastatic hormone-sensitive prostate cancer. 转移性激素敏感性前列腺癌症原发性癌症的治疗。
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-12-01 Epub Date: 2023-10-03 DOI: 10.1097/SPC.0000000000000676
Kylie Y-Y Lim, Matthew Alberto, Weranja Ranasinghe

Purpose of review: Recently, there has been emerging interest in the treatment of primary tumours in metastatic prostate cancer based on major trials that have provided evidence for radiation therapy and cytoreductive radical prostatectomy. Preclinical studies have further established the molecular features of metastatic disease that provide a rationale for primary treatment.

Recent findings: Several randomised controlled trials and other prospective studies have demonstrated a benefit in overall survival, predominantly in low-volume disease. Advancements in precision medicine also offer insight into improving selection, staging and monitoring.

Summary: In this review, the authors highlight and review recent data on emerging and established treatment options and shift towards personalised medicine for hormone-sensitive metastatic prostate cancer.

综述目的:最近,基于为放射治疗和细胞减灭性前列腺癌根治术提供证据的主要试验,人们对转移性前列腺癌症原发性肿瘤的治疗产生了新的兴趣。临床前研究进一步确定了转移性疾病的分子特征,为初步治疗提供了依据。最近的发现:几项随机对照试验和其他前瞻性研究已经证明了对总生存率的益处,主要是对低容量疾病。精准医学的进步也为改进选择、分期和监测提供了见解。摘要:在这篇综述中,作者强调并回顾了新出现的和已确定的治疗方案的最新数据,并转向激素敏感转移性前列腺癌症的个性化药物。
{"title":"Treatment of primary cancer in metastatic hormone-sensitive prostate cancer.","authors":"Kylie Y-Y Lim, Matthew Alberto, Weranja Ranasinghe","doi":"10.1097/SPC.0000000000000676","DOIUrl":"10.1097/SPC.0000000000000676","url":null,"abstract":"<p><strong>Purpose of review: </strong>Recently, there has been emerging interest in the treatment of primary tumours in metastatic prostate cancer based on major trials that have provided evidence for radiation therapy and cytoreductive radical prostatectomy. Preclinical studies have further established the molecular features of metastatic disease that provide a rationale for primary treatment.</p><p><strong>Recent findings: </strong>Several randomised controlled trials and other prospective studies have demonstrated a benefit in overall survival, predominantly in low-volume disease. Advancements in precision medicine also offer insight into improving selection, staging and monitoring.</p><p><strong>Summary: </strong>In this review, the authors highlight and review recent data on emerging and established treatment options and shift towards personalised medicine for hormone-sensitive metastatic prostate cancer.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":" ","pages":"315-323"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41173853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anxiety and post-traumatic stress disorders in patients with chronic respiratory diseases. 慢性呼吸系统疾病患者的焦虑和创伤后应激障碍
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-12-01 Epub Date: 2023-08-10 DOI: 10.1097/SPC.0000000000000670
Abebaw M Yohannes

Purpose of review: This brief critical review evaluates recent research on the impact of anxiety disorders and post-traumatic stress disorders (PTSD) on patients with chronic obstructive pulmonary disease (COPD) and asthma. In these patients, untreated anxiety and PTSD exacerbate acute symptoms, increase disability and impair quality of life. Therefore, effective interventions are also reviewed.

Recent findings: Anxiety disorders and PTSD are prevalent in COPD and asthma, worsen symptoms in acute exacerbations, and increase morbidity and healthcare utilization. Pulmonary rehabilitation (PR), cognitive behavioural therapy and pharmacological therapy are each effective in COPD patients with anxiety or PTSD. However, very little work examined therapy for combined anxiety and PTSD in patients with either COPD or asthma.

Summary: Despite the high prevalence of anxiety disorder or PTSD in patients with chronic respiratory diseases, a paucity of literature remains demonstrating the efficacy of pharmacological therapies for these conditions. This review highlights the promising benefits of PR on anxiety, but prospective trials are needed to demonstrate the efficacy of interventions with PTSD alone, or with concomitant anxiety.

综述目的:这篇简短的批判性综述评估了最近关于焦虑症和创伤后应激障碍(PTSD)对慢性阻塞性肺病(COPD)和哮喘患者影响的研究。在这些患者中,未经治疗的焦虑和创伤后应激障碍会加剧急性症状,增加残疾并损害生活质量。因此,还审查了有效的干预措施。最近的研究结果:焦虑症和创伤后应激障碍在COPD和哮喘中普遍存在,在急性加重时症状恶化,发病率和医疗利用率增加。肺康复(PR)、认知行为治疗和药物治疗对患有焦虑或PTSD的COPD患者都有效。然而,很少有研究对COPD或哮喘患者的合并焦虑和创伤后应激障碍进行治疗。摘要:尽管慢性呼吸系统疾病患者中焦虑症或创伤后应激障碍的患病率很高,但仍缺乏文献证明药物治疗对这些疾病的疗效。这篇综述强调了PR对焦虑的潜在益处,但需要进行前瞻性试验来证明单独治疗PTSD或伴随焦虑的干预措施的有效性。
{"title":"Anxiety and post-traumatic stress disorders in patients with chronic respiratory diseases.","authors":"Abebaw M Yohannes","doi":"10.1097/SPC.0000000000000670","DOIUrl":"10.1097/SPC.0000000000000670","url":null,"abstract":"<p><strong>Purpose of review: </strong>This brief critical review evaluates recent research on the impact of anxiety disorders and post-traumatic stress disorders (PTSD) on patients with chronic obstructive pulmonary disease (COPD) and asthma. In these patients, untreated anxiety and PTSD exacerbate acute symptoms, increase disability and impair quality of life. Therefore, effective interventions are also reviewed.</p><p><strong>Recent findings: </strong>Anxiety disorders and PTSD are prevalent in COPD and asthma, worsen symptoms in acute exacerbations, and increase morbidity and healthcare utilization. Pulmonary rehabilitation (PR), cognitive behavioural therapy and pharmacological therapy are each effective in COPD patients with anxiety or PTSD. However, very little work examined therapy for combined anxiety and PTSD in patients with either COPD or asthma.</p><p><strong>Summary: </strong>Despite the high prevalence of anxiety disorder or PTSD in patients with chronic respiratory diseases, a paucity of literature remains demonstrating the efficacy of pharmacological therapies for these conditions. This review highlights the promising benefits of PR on anxiety, but prospective trials are needed to demonstrate the efficacy of interventions with PTSD alone, or with concomitant anxiety.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":"17 4","pages":"290-295"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50159077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tackling respiratory problems - needs, education, and treatments. 解决呼吸问题——需求、教育和治疗。
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-12-01 Epub Date: 2023-10-26 DOI: 10.1097/SPC.0000000000000679
Magnus Ekström, Daisy J A Janssen
{"title":"Tackling respiratory problems - needs, education, and treatments.","authors":"Magnus Ekström, Daisy J A Janssen","doi":"10.1097/SPC.0000000000000679","DOIUrl":"10.1097/SPC.0000000000000679","url":null,"abstract":"","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":"17 4","pages":"253-254"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50159095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Goals of care and end-of-life communication needs of persons with chronic respiratory disease. 慢性呼吸道疾病患者的护理和临终沟通需求目标。
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-12-01 Epub Date: 2023-09-04 DOI: 10.1097/SPC.0000000000000672
Lynn F Reinke, Tracy Fasolino, Donald R Sullivan

Purpose of the review: To highlight recent advances in effective communication among persons with chronic respiratory diseases. The authors focus on communication science related to goals of care (GOC) discussions, medical devices, and life-sustaining invasive treatments. The authors discuss important considerations when working with individuals with low literacy and rurality. Communication handoffs between respiratory clinicians and/or palliative care to hospice clinicians are summarized to ensure effective person-centered and caregiver-centered care.

Recent findings: Studies suggest the following communication approaches: (1) clarify differences between palliative and end of life; (2) conduct conversations early and gradual throughout the illness trajectory; (3) distinguish types of GOC discussions as they relate to treatment preferences; (4) for patients from rural communities, include family members and spiritual leaders; (5) assess literacy and employ supportive strategies; (6) apply time-limited-trial framework for life-sustaining treatment (LST) decisions; and (7) standardize processes for communication handoffs to hospice clinicians to improve communication fidelity.

Summary: Effective communication tools for clinicians to engage in GOC discussions for persons with chronic respiratory diseases are grounded in a patient-centered framework. A trained clinician should lead these conversations and include interdisciplinary team members throughout the disease trajectory including at the end of life. These approaches may enable patients to express their values and care preferences as they evolve over time.

综述的目的:强调慢性呼吸系统疾病患者之间有效沟通的最新进展。作者专注于与护理目标(GOC)讨论、医疗设备和维持生命的侵入性治疗相关的传播科学。作者讨论了与低识字率和农村人口合作时的重要考虑因素。总结了呼吸科临床医生和/或姑息治疗与临终关怀临床医生之间的沟通交接,以确保有效的以人为中心和以护理者为中心的护理。最近的研究结果:研究提出了以下沟通方法:(1)阐明姑息治疗和生命终结之间的差异;(2) 在整个疾病发展过程中尽早、循序渐进地进行对话;(3) 区分GOC讨论的类型,因为它们与治疗偏好有关;(4) 对于来自农村社区的患者,包括家庭成员和精神领袖;(5) 评估识字率并采用支持性战略;(6) 对维持生命治疗(LST)决策应用限时试验框架;以及(7)将通信切换到临终关怀临床医生的过程标准化,以提高通信保真度。摘要:临床医生参与慢性呼吸系统疾病患者GOC讨论的有效沟通工具基于以患者为中心的框架。经过培训的临床医生应该领导这些对话,并在疾病发展过程中包括在生命结束时包括跨学科团队成员。随着时间的推移,这些方法可能使患者能够表达他们的价值观和护理偏好。
{"title":"Goals of care and end-of-life communication needs of persons with chronic respiratory disease.","authors":"Lynn F Reinke, Tracy Fasolino, Donald R Sullivan","doi":"10.1097/SPC.0000000000000672","DOIUrl":"10.1097/SPC.0000000000000672","url":null,"abstract":"<p><strong>Purpose of the review: </strong>To highlight recent advances in effective communication among persons with chronic respiratory diseases. The authors focus on communication science related to goals of care (GOC) discussions, medical devices, and life-sustaining invasive treatments. The authors discuss important considerations when working with individuals with low literacy and rurality. Communication handoffs between respiratory clinicians and/or palliative care to hospice clinicians are summarized to ensure effective person-centered and caregiver-centered care.</p><p><strong>Recent findings: </strong>Studies suggest the following communication approaches: (1) clarify differences between palliative and end of life; (2) conduct conversations early and gradual throughout the illness trajectory; (3) distinguish types of GOC discussions as they relate to treatment preferences; (4) for patients from rural communities, include family members and spiritual leaders; (5) assess literacy and employ supportive strategies; (6) apply time-limited-trial framework for life-sustaining treatment (LST) decisions; and (7) standardize processes for communication handoffs to hospice clinicians to improve communication fidelity.</p><p><strong>Summary: </strong>Effective communication tools for clinicians to engage in GOC discussions for persons with chronic respiratory diseases are grounded in a patient-centered framework. A trained clinician should lead these conversations and include interdisciplinary team members throughout the disease trajectory including at the end of life. These approaches may enable patients to express their values and care preferences as they evolve over time.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":" ","pages":"283-289"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10210858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial introductions. 编辑介绍。
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-12-01 Epub Date: 2023-10-26 DOI: 10.1097/SPC.0000000000000681
Anna Domolo

Current Opinion in Supportive and Palliative Care was launched in 2007. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of supportive and palliative care are divided into 12 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.

支持性和姑息性护理的当前意见于2007年发布。它是一系列成功的评论期刊之一,其独特的格式旨在对许多主要期刊上发表的文献进行系统和批判性的评估。支持性和姑息性护理领域分为12个部分,每年审查一次。每个章节都分配了一名章节编辑,这是该领域的主要权威,负责确定当时最重要的主题。在这里,我们很高兴为您介绍本期《华尔街日报》栏目编辑。
{"title":"Editorial introductions.","authors":"Anna Domolo","doi":"10.1097/SPC.0000000000000681","DOIUrl":"10.1097/SPC.0000000000000681","url":null,"abstract":"<p><p>Current Opinion in Supportive and Palliative Care was launched in 2007. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of supportive and palliative care are divided into 12 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":"17 4","pages":"i"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50159078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent advances in bronchoscopic lung volume reduction for severe COPD patients. 支气管镜下肺减容治疗重度COPD的最新进展。
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-12-01 Epub Date: 2023-10-26 DOI: 10.1097/SPC.0000000000000682
Rein Posthuma, Anouk W Vaes, Martijn A Spruit, Lowie E G W Vanfleteren

Purpose of review: Bronchoscopic lung volume reduction (BLVR) is a novel and effective treatment for a specific phenotype of chronic obstructive pulmonary disease (COPD) characterized by advanced emphysema with static lung hyperinflation and severe breathlessness. This review aims to provide an overview of the recent advances made in BLVR.

Recent findings: For achieving optimal outcomes with BLVR, patient selection and target lobe identification is crucial. BLVR has recently also been established to improve pulmonary function, exercise capacity and quality of life in COPD patients falling outside the standard treatment criteria, including patients with moderate hyperinflation, chronic hypercapnic failure or with very low diffusion capacity. In a cluster analysis, target lobe characteristics like emphysema destruction, air trapping and perfusion were found to be important discriminators between responders and non-responders. A potential survival benefit has been demonstrated in BLVR-treated patients when compared to non-treated patients. Long-term outcomes showed sustained outcomes of BLVR; however, effects decline over time, probably due to disease progression.

Summary: BLVR using one-way endobronchial valves has become a guideline treatment offered in specialized intervention centres for a specific subgroup of COPD patients. Recent studies further characterize responders, describe extrapulmonary effects of BLVR and show positive long-term outcomes and a potential survival benefit.

综述目的:支气管镜肺减容术(BLVR)是一种新的有效治疗慢性阻塞性肺病(COPD)的特殊表型的方法,其特征是晚期肺气肿伴静止性肺过度充气和严重呼吸困难。这篇综述旨在概述BLVR的最新进展。最近的发现:为了实现BLVR的最佳结果,患者选择和靶叶识别至关重要。BLVR最近也被建立起来,以改善标准治疗标准之外的COPD患者的肺功能、运动能力和生活质量,包括中度高充气、慢性高碳酸血症衰竭或扩散能力极低的患者。在聚类分析中,发现肺气肿破坏、空气捕获和灌注等靶叶特征是区分应答者和非应答者的重要因素。与未接受治疗的患者相比,BLVR治疗的患者具有潜在的生存益处。长期结果显示BLVR的持续结果;然而,效果会随着时间的推移而下降,可能是由于疾病的进展。总结:使用单向支气管内瓣膜的BLVR已成为专门干预中心针对COPD患者特定亚组提供的指导性治疗方法。最近的研究进一步描述了应答者的特征,描述了BLVR的肺外效应,并显示了积极的长期结果和潜在的生存益处。
{"title":"Recent advances in bronchoscopic lung volume reduction for severe COPD patients.","authors":"Rein Posthuma, Anouk W Vaes, Martijn A Spruit, Lowie E G W Vanfleteren","doi":"10.1097/SPC.0000000000000682","DOIUrl":"10.1097/SPC.0000000000000682","url":null,"abstract":"<p><strong>Purpose of review: </strong>Bronchoscopic lung volume reduction (BLVR) is a novel and effective treatment for a specific phenotype of chronic obstructive pulmonary disease (COPD) characterized by advanced emphysema with static lung hyperinflation and severe breathlessness. This review aims to provide an overview of the recent advances made in BLVR.</p><p><strong>Recent findings: </strong>For achieving optimal outcomes with BLVR, patient selection and target lobe identification is crucial. BLVR has recently also been established to improve pulmonary function, exercise capacity and quality of life in COPD patients falling outside the standard treatment criteria, including patients with moderate hyperinflation, chronic hypercapnic failure or with very low diffusion capacity. In a cluster analysis, target lobe characteristics like emphysema destruction, air trapping and perfusion were found to be important discriminators between responders and non-responders. A potential survival benefit has been demonstrated in BLVR-treated patients when compared to non-treated patients. Long-term outcomes showed sustained outcomes of BLVR; however, effects decline over time, probably due to disease progression.</p><p><strong>Summary: </strong>BLVR using one-way endobronchial valves has become a guideline treatment offered in specialized intervention centres for a specific subgroup of COPD patients. Recent studies further characterize responders, describe extrapulmonary effects of BLVR and show positive long-term outcomes and a potential survival benefit.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":"17 4","pages":"296-300"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50159094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial introductions. 编辑介绍。
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-12-01 Epub Date: 2023-10-26 DOI: 10.1097/SPC.0000000000000681
Anna Domolo

Current Opinion in Supportive and Palliative Care was launched in 2007. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of supportive and palliative care are divided into 12 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.

《支持和姑息治疗的当前意见》于2007年推出。它是一系列成功的评论期刊之一,其独特的格式旨在提供许多主要期刊中提出的文献的系统和批判性评估。支持和姑息治疗领域分为12个部分,每年审查一次。每个章节都有一个章节编辑,他是该领域的权威,负责确定当时最重要的主题。在这里,我们很高兴地介绍本刊的栏目编辑。
{"title":"Editorial introductions.","authors":"Anna Domolo","doi":"10.1097/SPC.0000000000000681","DOIUrl":"https://doi.org/10.1097/SPC.0000000000000681","url":null,"abstract":"<p><p>Current Opinion in Supportive and Palliative Care was launched in 2007. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of supportive and palliative care are divided into 12 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":"17 4","pages":"i"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138441434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Opinion in Supportive and Palliative Care
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1